S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
All the trading advice you’ve ever received boils down to this (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
All the trading advice you’ve ever received boils down to this (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
All the trading advice you’ve ever received boils down to this (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
All the trading advice you’ve ever received boils down to this (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
All the trading advice you’ve ever received boils down to this (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
All the trading advice you’ve ever received boils down to this (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
All the trading advice you’ve ever received boils down to this (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
All the trading advice you’ve ever received boils down to this (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way

Evofem Biosciences (EVFM) Stock Price, News & Analysis

$0.07
0.00 (0.00%)
(As of 12/8/2023 ET)
Compare
Today's Range
$0.07
$0.07
50-Day Range
$0.06
$0.17
52-Week Range
$0.06
$10.63
Volume
33,851 shs
Average Volume
160,375 shs
Market Capitalization
$824,600.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

EVFM stock logo

About Evofem Biosciences Stock (NASDAQ:EVFM)

Evofem Biosciences, Inc., is a small biopharmaceutical company with a single commercial product as well as a pipeline of potential winners. The company works to develop and commercialize a variety of product lines intended to address unmet needs in women’s sexual and reproductive health. The company’s motto is Science With A Soul and its aim is to improve women’s lives with innovative solutions. In fact, the sole purpose of the company is to improve the quality of women’s lives by enabling greater control of their healthcare needs.

Evofem Biosciences went public in January 2018. The company is headquartered in San Diego, California, and is led by Saundra Pelletier. Ms. Pelletier has been CEO, president, and executive director of the company since February 2015 and is instrumental in the company’s transition to a publicly traded issue. Ms. Pelletier has more than 25 years of experience in the pharmaceutical industry and is responsible for launching and expanding the use of many brands.

Evofem’s primary commercial product is Phexxi. Phexxi is a vaginal gel for the prevention of pregnancy. Phexxi is the US first and only hormone-free prescription birth control product that is controlled by the individual. It stands out from other methods because it is hormone free, requires no daily usage, comes with no invasive procedures, and is easy to carry in a bag and use when needed.

Phexxi works by maintaining vaginal pH after intercourse and relies on 3 naturally occurring chemicals that are regularly found in food: lactic acid, citric acid, and potassium bitartrate (cream of tartar for the chefs out there). The product works because sperm need a higher pH to thrive than what is normal in women’s health and that is provided by the semen. Phexxi’s acidic composition is formulated to maintain the ideal pH and keep the sperm inactive. Phexxi can also block the cervical opening and prevent sperm from entering.

Among the many advantages of Phexxi are reduced or non-existent side effects as compared to other forms of birth control which include mood swings, headaches, and irritability. The product is approved by the FDA and prescriptions can be filled via telehealth appointment. The company estimates each 100 basis points of US market share it can secure is worth $300 million in annual revenue.

The opportunity for Evofem is that its product, Phexxi, has been shown to be effective in fighting the transmission of gonorrhea and chlamydia. The transmission of both STDs has been associated with higher pH levels which Phexxi is specifically fighting. The investigational drug EV-100 (Phexxi) has made it through to Phase 3 clinical testing and regulatory filings are expected. The company also has two other products in development and they are on track to enter clinical trials.

 

EVFM Stock Price History

EVFM Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Evofem Biosciences (OTC: EVFM)
EVFM - Evofem Biosciences, Inc.
See More Headlines
Receive EVFM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evofem Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2023
Today
12/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EVFM
Employees
35
Year Founded
N/A

Profitability

Net Income
$-76,700,000.00
Pretax Margin
345.00%

Debt

Sales & Book Value

Annual Sales
$16.84 million
Book Value
($62.94) per share

Miscellaneous

Free Float
12,374,000
Market Cap
$824,600.00
Optionable
Not Optionable
Beta
-1.20
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives















EVFM Stock Analysis - Frequently Asked Questions

How have EVFM shares performed in 2023?

Evofem Biosciences' stock was trading at $8.00 at the beginning of 2023. Since then, EVFM stock has decreased by 99.2% and is now trading at $0.0665.
View the best growth stocks for 2023 here
.

How were Evofem Biosciences' earnings last quarter?

Evofem Biosciences, Inc. (NASDAQ:EVFM) posted its earnings results on Tuesday, November, 14th. The biotechnology company reported $0.10 EPS for the quarter. The biotechnology company had revenue of $5.11 million for the quarter. Evofem Biosciences had a net margin of 344.82% and a negative trailing twelve-month return on equity of 77.85%.

When did Evofem Biosciences' stock split?

Evofem Biosciences shares reverse split on the morning of Thursday, May 18th 2023. The 1-125 reverse split was announced on Thursday, May 18th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What other stocks do shareholders of Evofem Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evofem Biosciences investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Sorrento Therapeutics (SRNE), Bionano Genomics (BNGO), Zosano Pharma (ZSAN), Aeterna Zentaris (AEZS), Organigram (OGI), Gran Tierra Energy (GTE), Novan (NOVN) and KushCo (KSHB).

How do I buy shares of Evofem Biosciences?

Shares of EVFM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:EVFM) was last updated on 12/10/2023 by MarketBeat.com Staff

My Account -